Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733666 | 1.00 | ROCK2 (0.46) | ROCK2ALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15272310 | 0.85 | ROCK2 (0.44) | ROCK2ALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31384427 | 0.79 | ROCK2 (0.52) | ROCK2 | |
| SCHEMBL675878 | 0.79 | ROCK2 (0.52) | ROCK2 | |
| SCHEMBL21348992 | 0.76 | ROCK2 (0.38) | ROCK2ALDH1A1 | |
| SCHEMBL17930294 | 0.73 | ROCK2 (0.48) | ROCK2 | |
| SCHEMBL31152065 | 0.73 | ROCK2 (0.48) | ROCK2 | |
| SCHEMBL2226101 | 0.72 | ROCK2 (0.39) | ROCK2ALDH1A1 | |
| SCHEMBL21096900 | 0.72 | ROCK2 (0.51) | ROCK2ALDH1A1CYP3A4 | |
| SCHEMBL8761366 | 0.71 | HSP90AA1 (0.41) | CYP2C9CYP2C19HSP90AA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127248-A1 | PREPARATION METHOD FOR MORPHOLINQUINAZOLINE COMPOUND AND MIDBODY THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2022-04-28 | — | — | US | claimed |
| EP-2563775-B1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-01-04 | — | — | EP | claimed |
| US-12595408-B2 | Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses | TOKUYAMA CORPORATION (JP) | 2026-04-07 | — | — | US | disclosed |
| EP-4692072-A1 | PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20250122163-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2025-04-17 | — | — | US | disclosed |
| US-20250101294-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2025-03-27 | — | — | US | disclosed |
| WO-2025041624-A1 | PHOTOCHROMIC COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2025-02-27 | — | — | WO | disclosed |
| EP-4471018-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2024-12-04 | — | — | EP | disclosed |
| EP-4467547-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024202087-A1 | PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES | 株式会社トクヤマ | 2024-10-03 | — | — | WO | disclosed |
| CN-118574818-A | Photochromic compound, naphthol derivative, curable composition, optical article, lens and spectacles | 株式会社德山 | 2024-08-30 | — | — | CN | disclosed |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | PFIZER (US) | 2014-01-02 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061074-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061081-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| EP-2563775-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135376-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | MAP3K5, MAP3K1, MAP4K2 | ROCK2 479/4885ALDH1A1 3640/4885CYP3A4 1293/4885 |
| US-12595408-B2 | Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses | CRYAA, CRYZ, CRY2 | ROCK2 2391/4885ALDH1A1 185/4885CYP3A4 1098/4885 |
| US-20250122163-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | CCNE1, NAP1L1, CRYZ | ROCK2 1292/4885ALDH1A1 1010/4885CYP3A4 2008/4885 |
| US-20220127248-A1 | PREPARATION METHOD FOR MORPHOLINQUINAZOLINE COMPOUND AND MIDBODY THEREOF | MDK, MYLK4, MYL4 | ROCK2 208/4885ALDH1A1 4391/4885CYP3A4 802/4885 |
| US-20250101294-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | NAP1L1, CRYAA, CRYZ | ROCK2 2874/4885ALDH1A1 224/4885CYP3A4 2238/4885 |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | UGT2B7, NAT1, CYP2B6 | ROCK2 4514/4885ALDH1A1 1115/4885CYP3A4 12/4885 |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | ROCK2 1300/4885ALDH1A1 1441/4885CYP3A4 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.